THERAPEUTIC OR PREVENTING AGENT FOR ENDOMETRIOSIS

摘要

PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition for treating and preventing endometriosis capable of reducing adverse effects of an antiestrogen agent to the utmost by using the antiestrogen agent as an active ingredient and adopting a design so as to administer the composition according to a specific usage. SOLUTION: This pharmaceutical composition contains an antiestrogen agent e.g. (6-hydroxy-2-cyclohexylbenzo[b]thien-3-yl)[4-[2-(1-piperidinyl) ethoxy]phenyl]methane hydrochloride} as an active ingredient and is administered for consecutive 5-13 days, preferably only 7-9 days during the period of time from the menstrual period of the menstrual cycle to the time just before the ovulation. The time of starting the administration is preferably the 3-5th days after the commencement of menstruation of each menstrual cycle. The time of completing the administration is preferably the 9-11th days after the commencement of the menstruation of each menstrual cycle. When the pharmaceutical preparation is in a solid or a semisolid form, the antiestrogen agent is preferably contained in an amount of 0.1-50 wt.%. When the pharmaceutical preparation is in a liquid form, the agent is preferably contained in an amount of 0.05-10 wt.%. The daily does thereof is preferably 30-600 mg.